Telomerase Activity and Proliferation Index in Aggressive Mature B-Cell Lymphoma: Comparison to Germinal Center Phenotypic Markers

Human Pathology

Volumn 34, Issue 12, 2003, Pages 1259-1264

  Chiu, Katharine C ^a,c   Fine, Miriam ^a   Ikle, David ^a   Slovak, Marilyn L ^a   Arber, Daniel A ^a,b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Diffuse large cell lymphoma; Ki 67; Proliferation; Telomerase

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN BCL 6; TELOMERASE;

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CELL HYPERPLASIA; CELL PROLIFERATION; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME ACTIVITY; EVALUATION; FOLLICULAR LYMPHOMA; GERMINAL CENTER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MANTLE CELL LYMPHOMA; PHENOTYPE; PROLIFERATION INDEX; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

EID: 0347623320     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2003.07.009     Document Type: Article

References (40)

1. Jaffe ES, Harris NL, Stein H, et al (eds): World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001
2. Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
3. Gerdes J, Stein H, Pileri S, et al: Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet 2:448-449, 1987
4. Sanchez-Beato M, Saez AI, Navas IC, et al: Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol 159:205-213, 2001
5. Ohyashiki JH, Sashida G, Tauchi T, et al: Telomeres and telomerase in hematologic neoplasia. Oncogene 21:680-687, 2002
6. Miller TP, Grogan TM, Dahlberg S, et al: Prognostic significance of Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: A prospective Southwest Oncology Group trial. Blood 83:1460-1466, 1994
7. Gerdes J, Lemke H, Baisch H, et al: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710-1715, 1984
8. Pich A, Ponti R, Valente G, et al: MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate-grade malignant lymphomas. J Clin Pathol 47:18-22, 1994
9. Palestro G, Pich A, Chiusa L, et al: Biological heterogeneity of diffuse mixed small and large cell non-Hodgkin's lymphomas assessed by DNA flow cytometry and Ki67. Leuk Lymphoma 19:467-472, 1995
10. Schmitt F, Tani E, Tribukait B, et al: Assessment of cell proliferation by Ki-67 staining and flow cytometry in fine-needle aspirates (FNAs) of reactive lymphadenitis and non- Hodgkin's lymphomas. Cytopathology 10:87-96, 1999
11. Gerdes J, Dallenbach F, Lennert K, et al: Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 2:365-371, 1984
12. Grogan TM, Lippman SM, Spier CM, et al: Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 71:1157-1160, 1988
13. Hall PA, Richards MA, Gregory WM, et al: The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 154:223-235, 1988
14. Meyerson M: Role of telomerase in normal and cancer cells. J Clin Oncol 18:2626-2634, 2000
15. Buys CH: Telomeres, telomerase, and cancer. N Engl J Med 342:1282-1283, 2000
16. MacNamara B, Wang W, Chen Z, et al: Telomerase activity in relation to pro- and anti-apoptotic protein expression in high-grade non-Hodgkin's lymphomas. Haematologica 86:386-393, 2001
17. Matthews P, Jones CJ: Clinical implications of telomerase detection. Histopathology 38:485-498, 2001
18. Greider CW: Telomerase activity, cell proliferation, and cancer. Proc Natl Acad Sci U S A 95:90-92, 1998
19. Belair CD, Yeager TR, Lopez PM, et al: Telomerase activity: A biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci U S A 94:13677-13682, 1997
20. Igarashi H, Sakaguchi N: Telomerase activity is induced by the stimulation to antigen receptor in human peripheral lymphocytes. Biochem Biophys Res Commun 219:649-655, 1996
21. Norrback KF, Dahlenborg K, Carlsson R, et al: Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas. Blood 88:222-229, 1996
22. Gown AM, de Wever N, Battifora H: Microwave-based antigenic unmasking: A revolutionary new technique for routine immunohistochemistry. Appl Immunohistochem 1:256-266, 1993
23. Sheibani K, Tubbs RR: Enzyme immunohistochemistry: Technical aspects. Semin Diagn Pathol 1:235-250, 1984
24. Liu J, Johnson RM, Traweek ST: Rearrangement of the BCL-2 gene in follicular lymphoma. Detection by PCR in both fresh and fixed tissue samples. Diagn Mol Pathol 2:241-247, 1993
25. Braziel RM, Arber DA, Slovak ML, et al: The Burkitt-like lymphomas: A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood 97:3713-3720, 2001
26. Fiel-Gan MD, Almeida LM, Rose DC, et al: Proliferative fraction, bcl-1 gene translocation, and p53 mutation status as markers in mantle cell lymphoma. Int J Mol Med 3:373-379, 1999
27. Weiss LM, Strickler JG, Medeiros LJ, et al: Proliferative rates of non-Hodgkin's lymphomas as assessed by Ki-67 antibody. HUM PATHOL 18:1155-1159, 1987
28. Ely SA, Chadburn A, Dayton CM, et al: Telomerase activity in B-cell non-Hodgkin's lymphoma. Cancer 89:445-452, 2000
29. Okayasu I, Mitomi H, Yamashita K, et al: Telomerase activity significantly correlates with cell differentiation, proliferation and lymph node metastasis in colorectal carcinomas. J Cancer Res Clin Oncol 124:444-449, 1998
30. Arber DA: Molecular diagnostic approach to non-Hodgkin's lymphoma. J Mol Diag 2:178-190, 2000
31. Sanchez E, Chacon I, Plaza MM, et al: Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 16:1931-1939, 1998
32. Korkolopoulou P, Angelopoulou MK, Kontopidou F, et al: Prognostic relevance of apoptotic cell death in non-Hodgkin's lymphomas: A multivariate survival analysis including Ki67 and p53 oncoprotein expression. Histopathology 33:240-247, 1998
33. Zhang A, Ohshima K, Sato K, et al: Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol Int 49:1043-1052, 1999
34. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
35. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
36. Ree HJ, Yang WI, Kim CW, et al: Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: Significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma. HUM PATHOL 32:954-962, 2001
37. Barrans SL, Carter I, Owen RG, et al: Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99:1136-1143, 2002
38. Huang JZ, Sanger WG, Greiner TC, et al: The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 99:2285-2290, 2002
39. Gascoyne RD, Adomat SA, Krajewski S, et al: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangements in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244-251, 1997
40. Winter JN, Andersen J, Reed JC, et al: BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. Blood 91:1391-1398, 1998